TY - JOUR
T1 - Detection of rare mutations, copy number alterations, and methylation in the same template DNA molecules
AU - Wang, Yuxuan
AU - Douville, Christopher
AU - Cohen, Joshua D.
AU - Mattox, Austin
AU - Curtis, Sam
AU - Silliman, Natalie
AU - Popoli, Maria
AU - Ptak, Janine
AU - Dobbyn, Lisa
AU - Nehme, Nadine
AU - Dudley, Jonathan C.
AU - Summers, Mahmoud
AU - Zhang, Ming
AU - Ho-Pham, Lan T.
AU - Tran, Bich N.H.
AU - Tran, Thach S.
AU - Nguyen, Tuan V.
AU - Bettegowda, Chetan
AU - Papadopoulos, Nickolas
AU - Kinzler, Kenneth W.
AU - Vogelstein, Bert
N1 - Funding Information:
ACKNOWLEDGMENTS. We thank the individuals who participated in this study for their courage and generosity. We also thank Dr. S. Markowitz for insightful comments and review of this manuscript.We are grateful to C.Blair and K.Judge for expert technical and administrative assistance and to E. Cook for illustrative assistance.This work was supported by The Lustgarten Foundation for Pancreatic
Funding Information:
Cancer Research,The Virginia and 297 D.K.Ludwig Fund for Cancer Research,The Conrad N.Hilton Foundation,The Sol Goldman Charitable Foundation,Burroughs Wellcome Fund Career Award for Medical Scientists, the Commonwealth Foundation, NCATS 1R21TR004059, NINDS R21NS113016, and National Cancer Institute grants/NIH grants (R37 CA230400, U01 CA200469, U01 CA62924, U01 CA06973, U01 CA230691, T32 GM136577, and T32 CA009071).
Publisher Copyright:
Copyright © 2023 the Author(s).
PY - 2023/4/11
Y1 - 2023/4/11
N2 - The analysis of cell-free DNA (cfDNA) from plasma offers great promise for the earlier detection of cancer. At present, changes in DNA sequence, methylation, or copy number are the most sensitive ways to detect the presence of cancer. To further increase the sensitivity of such assays with limited amounts of sample, it would be useful to be able to evaluate the same template molecules for all these changes. Here, we report an approach, called MethylSaferSeqS, that achieves this goal, and can be applied to any standard library preparation method suitable for massively parallel sequencing. The innovative step was to copy both strands of each DNA-barcoded molecule with a primer that allows the subsequent separation of the original strands (retaining their 5-methylcytosine residues) from the copied strands (in which the 5-methylcytosine residues are replaced with unmodified cytosine residues). The epigenetic and genetic alterations present in the DNA molecules can then be obtained from the original and copied strands, respectively. We applied this approach to plasma from 265 individuals, including 198 with cancers of the pancreas, ovary, lung, and colon, and found the expected patterns of mutations, copy number alterations, and methylation. Furthermore, we could determine which original template DNA molecules were methylated and/or mutated. MethylSaferSeqS should be useful for addressing a variety of questions relating genetics and epigenetics.
AB - The analysis of cell-free DNA (cfDNA) from plasma offers great promise for the earlier detection of cancer. At present, changes in DNA sequence, methylation, or copy number are the most sensitive ways to detect the presence of cancer. To further increase the sensitivity of such assays with limited amounts of sample, it would be useful to be able to evaluate the same template molecules for all these changes. Here, we report an approach, called MethylSaferSeqS, that achieves this goal, and can be applied to any standard library preparation method suitable for massively parallel sequencing. The innovative step was to copy both strands of each DNA-barcoded molecule with a primer that allows the subsequent separation of the original strands (retaining their 5-methylcytosine residues) from the copied strands (in which the 5-methylcytosine residues are replaced with unmodified cytosine residues). The epigenetic and genetic alterations present in the DNA molecules can then be obtained from the original and copied strands, respectively. We applied this approach to plasma from 265 individuals, including 198 with cancers of the pancreas, ovary, lung, and colon, and found the expected patterns of mutations, copy number alterations, and methylation. Furthermore, we could determine which original template DNA molecules were methylated and/or mutated. MethylSaferSeqS should be useful for addressing a variety of questions relating genetics and epigenetics.
KW - biomarker
KW - cfDNA
KW - copy number alteration
KW - methylation
KW - mutation
UR - http://www.scopus.com/inward/record.url?scp=85151800195&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85151800195&partnerID=8YFLogxK
U2 - 10.1073/pnas.2220704120
DO - 10.1073/pnas.2220704120
M3 - Article
C2 - 37014860
AN - SCOPUS:85151800195
SN - 0027-8424
VL - 120
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 15
M1 - e2220704120
ER -